Lucid Diagnostics Inc. (LUCD) stock
LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3034% above fair value
$0.40+0.00 (+0.30%)
Close on Nov 17, 2026Market cap $81.09MP/E –Yield –
Lucid Diagnostics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Lucid Diagnostics's price to book ratio was 6.7× on Nov 11, 2026, against 5.4× a year earlier. Over the last 4 years it ranged from 1.3× to 44.1×, with a median of 4.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.7× | +1.1 |
| 2025 | Dec 31, 2025 | 5.5× | −1.1 |
| 2024 | Dec 31, 2024 | 6.7× | −16.7 |
| 2023 | Dec 29, 2023 | 23.4× | +21.5 |
| 2022 | Dec 30, 2022 | 1.8× | – |
See a number that looks wrong?